Iovance Biotherapeutics(US:IOVA) Globenewswire·2025-10-08 19:05Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Iovance Biotherapeutics, Inc. due to a class action complaint alleging breaches of fiduciary duties by the company's board of directors during the specified class period from May 9, 2024, to May 8, 2025 [1][6]. Company Overview - Iovance Biotherapeutics, Inc. is facing scrutiny following a class action complaint filed on May 15, 2025, which claims that the company misled investors about its growth potential and operational capabilities [1][6]. - The complaint alleges that Iovance provided overly positive statements while concealing material adverse facts regarding its ability to generate demand for its treatments [6]. Financial Performance - On July 25, 2024, Iovance announced its second-quarter financial results for fiscal 2024, which included a reduction in revenue guidance for the full fiscal year 2024 [6]. - The company attributed its disappointing results and lowered guidance to several factors: scheduled maintenance of the iCTC, lower-than-expected Proleukin sales, and the variable pace of treatment initiation by approved treatment centers [6]. Stock Price Impact - Following the announcement of the reduced revenue guidance, Iovance's stock price experienced a significant decline, dropping from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, representing a decrease of approximately 44.8% in just one day [6].